Gianluca Terrin1, Francesca Conte2, Mehmet Yekta Oncel3, Antonella Scipione2, Patrick J McNamara4, Sinno Simons5, Rahul Sinha6, Omer Erdeve7, Kadir S Tekgunduz8, Mustafa Dogan9, Irena Kessel10, Cathy Hammerman11, E Nadir12, Sadik Yurttutan3, Bonny Jasani13, Serdar Alan14, Francesco Manguso15, Mario De Curtis2. 1. Department of Gynecology-Obstetrics and Perinatal Medicine, Sapienza University of Rome, Rome, Italy. 2. Department of Pediatrics and Pediatric Neuropsychiatry, Sapienza University of Rome, Rome, Italy. 3. Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey. 4. Department of Neonatology, The Hospital for Sick Children, Toronto, Canada. 5. Division of Neonatology, Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 6. Department of Pediatrics and Neonatology, 167 Military Hospital, Pathankot, Punjab, India. 7. Division of Neonatology, Department of Pediatrics, Ankara University School of Medicine Children's Hospital, Ankara, Turkey. 8. Department of Neonatology, Ataturk University Medical Faculty, Erzurum, Turkey. 9. Division of Cardiology, Department of Pediatrics, Pamukkale University, Denizli, Turkey. 10. Department of Neonatology, Carmel Medical Center, Haifa, Israel. 11. Department of Neonatology, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel. 12. Department of Neonatology, Hillel Yaffe Medical Center, Hadera, Israel. 13. Department of Neonatology, KEM Hospital, Mumbai, India. 14. Division of Neonatology, Hitit University, Corum, Turkey. 15. Division of Gastroenterology, Cardarelli Hospital, Naples, Italy.
Abstract
OBJECTIVES: We performed a systematic review and meta-analysis of all the available evidence to assess the efficacy and safety of paracetamol for the treatment of patent ductus arteriosus (PDA) in neonates, and to explore the effects of clinical variables on the risk of closure. DATA SOURCE: MEDLINE, Scopus and ISI Web of Knowledge databases, using the following medical subject headings and terms: paracetamol, acetaminophen and patent ductus arteriosus. Electronic and manual screening of conference abstracts from international meetings of relevant organisations. Manual search of the reference lists of all eligible articles. STUDY SELECTION: Studies comparing paracetamol versus ibuprofen, indomethacin, placebo or no intervention for the treatment of PDA. DATA EXTRACTION: Data regarding efficacy and safety were collected and analysed. RESULTS: Sixteen studies were included: 2 randomised controlled trials (RCTs) and 14 uncontrolled studies. Quality of selected studies is poor. A meta-analysis of RCTs does not demonstrate any difference in the risk of ductal closure (Mantel-Haenszel model, RR 1.07, 95% CI 0.87 to 1.33 and RR 1.03, 95% CI 0.92 to 1.16, after 3 and 6 days of treatment, respectively). Proportion meta-analysis of uncontrolled studies demonstrates a pooled ductal closure rate of 49% (95% CI 29% to 69%) and 76% (95% CI 61% to 88%) after 3 and 6 days of treatment with paracetamol, respectively. Safety profiles of paracetamol and ibuprofen are similar. CONCLUSIONS: Efficacy and safety of paracetamol appear to be comparable with those of ibuprofen. These results should be interpreted with caution, taking into account the non-optimal quality of the studies analysed and the limited number of neonates treated with paracetamol so far. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: We performed a systematic review and meta-analysis of all the available evidence to assess the efficacy and safety of paracetamol for the treatment of patent ductus arteriosus (PDA) in neonates, and to explore the effects of clinical variables on the risk of closure. DATA SOURCE: MEDLINE, Scopus and ISI Web of Knowledge databases, using the following medical subject headings and terms: paracetamol, acetaminophen and patent ductus arteriosus. Electronic and manual screening of conference abstracts from international meetings of relevant organisations. Manual search of the reference lists of all eligible articles. STUDY SELECTION: Studies comparing paracetamol versus ibuprofen, indomethacin, placebo or no intervention for the treatment of PDA. DATA EXTRACTION: Data regarding efficacy and safety were collected and analysed. RESULTS: Sixteen studies were included: 2 randomised controlled trials (RCTs) and 14 uncontrolled studies. Quality of selected studies is poor. A meta-analysis of RCTs does not demonstrate any difference in the risk of ductal closure (Mantel-Haenszel model, RR 1.07, 95% CI 0.87 to 1.33 and RR 1.03, 95% CI 0.92 to 1.16, after 3 and 6 days of treatment, respectively). Proportion meta-analysis of uncontrolled studies demonstrates a pooled ductal closure rate of 49% (95% CI 29% to 69%) and 76% (95% CI 61% to 88%) after 3 and 6 days of treatment with paracetamol, respectively. Safety profiles of paracetamol and ibuprofen are similar. CONCLUSIONS: Efficacy and safety of paracetamol appear to be comparable with those of ibuprofen. These results should be interpreted with caution, taking into account the non-optimal quality of the studies analysed and the limited number of neonates treated with paracetamol so far. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Robert B Flint; Daniella W Roofthooft; Anne van Rongen; Richard A van Lingen; Johannes N van den Anker; Monique van Dijk; Karel Allegaert; Dick Tibboel; Catherijne A J Knibbe; Sinno H P Simons Journal: Pediatr Res Date: 2017-06-21 Impact factor: 3.756